Product Pathways - Growth Factors/Cytokines
Human His6IGFBP3 (hHis6IGFBP3) #12579
|12579LC||50 µg (With Carrier)||---||In Stock||---|
|12579LF||50 µg (Carrier Free)||---||In Stock||---|
|12579SF||10 µg (Carrier Free)||---||In Stock||---|
|12579SC||10 µg (With Carrier)||---||In Stock||---|
Already purchased this product? Write a Review.
Recombinant Human His6IGFBP3 (hHis6IGFBP3) Gly28-Lys291 (Accession #NP_17936) was expressed in human 293 cells at Cell Signaling Technology.
Recombinant N-terminally His6-tagged hIGFBP3 has a calculated MW of 30,7123 Da. DTT reduced and nonreduced protein migrate as 50 kDa polypeptides. Lower mobility and heterogeneity in SDS-PAGE are due to glycosylation. The expected amino terminus of recombinant hHis6IGFBP3 was verified by amino acid sequencing.
>95% as determined by SDS-PAGE of 6 μg reduced (+) and nonreduced (-) recombinant hHisIGFBP3. All lots are greater than 95% pure.
The bioactivity of hHis6IGFBP3 was determined by inhibition of IGF-I induced AKT phosphorylation in human dermal fibroblasts. The ED50 of each lot is between 2.5-9 ng/ml.
The purity of recombinant hHis6 IGFBP3 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant
hHis6 IGFBP3 and staining overnight with Coomassie Blue.
The inhibition of IGF-I induced Akt phosphorylation by hHis6IGFBP3. Human dermal fibroblasts were treated with Human Insulin-like Growth Factor I (hIGF-I) # 8917 in the presence or absence of increasing concentrations of hHis6IGFBP3 for 10 minutes, lysed, and Akt1 (Ser473) phosphorylation was quantified using the PathScan® Phospho-Akt1 (Ser473) Sandwich ELISA Kit #7160.
Less than 0.01 ng endotoxin/1 μg hHis6IGFBP3.
With carrier: Lyophilized from a 0.22 μm filtered solution of hHis6IGFBP3 in 20 mM Tris, pH 7.2 containing 20 μg BSA per 1 μg hHis6IGFBP3. Carrier free: Lyophilized from a 0.22 μm filtered solution of hHis6IGFBP3 in 20 mM Tris, pH 7.2.
IGFBP3 is a multifunctional protein that plays a key role in regulation of IGFI/II activity, cell proliferation, and death. One of six high-affinity IGF binding proteins, IGFBP3 is the major species in circulation and is bound in a complex with ALS to 99% of hepatic IGF-I (1). Proteolytic degradation of IGFBP3 increases the bioavailability and activity of the IGF I/II (1). However, some biological activities of IGFBP3 are independent of the IGF/IGF-IR axis. IGFBP3 potentiates EGF-induced breast cancer cell proliferation in vitro by enhancing ERK phosphorylation and sphingosine kinase-mediated EGFR trans-activation (2,3). Conversely, IGFBP3 has been shown to induce apoptosis and inhibit NF-κB activity (4).
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
PathScan® is a trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.